Theravance Biopharma, Inc. (TBPH): Free Cash Flow
$238.50M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $238.50M | n/m | 2026-03-23, From 2025-01-01 |
| 2024-12-31 | -$11.87M | n/m | 2026-03-23, From 2024-01-01 |
| 2023-12-31 | -$29.48M | n/m | 2025-03-07, From 2023-01-01 |
| 2022-12-31 | -$187.56M | n/m | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | -$211.26M | n/m | 2023-03-01, From 2021-01-01 |
| 2020-12-31 | -$257.02M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$241.37M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$120.11M | n/m | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | -$203.46M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$101.12M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$171.50M | n/m | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | -$178.26M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$123.69M | n/m | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | -$121.70M | n/a | 2015-03-13, From 2012-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $238.50M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | -$2.43M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$34.53M | n/m |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$162.73M | n/m |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | -$180.0K | n/m |
| Xencor Inc (XNCR) | 2025-12-31 | -$138.27M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$13.62M | n/m |
| Cytokinetics Inc (CYTK) | 2025-12-31 | -$534.82M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$82.65M | n/m |
Compare TBPH, ZVRA, ZYME, URGN side by side · Screen every company in Pharmaceutical Preparations ↗